NCT06996782 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT06996782
Title	A Platform Study in Non-Small Cell Lung Cancer (NSCLC) (ALTAIR)
Acronym	ALTAIR
Recruitment	Not yet recruiting
Gender	both
Phase	Phase Ib/II
Variant Requirements	Yes
Sponsors	AstraZeneca
Indications	lung non-squamous non-small cell carcinoma lung squamous cell carcinoma
Therapies	AZD2936 + Cisplatin + Pemetrexed Disodium AZD2936 + Carboplatin + Pemetrexed Disodium AZD2936 + Cisplatin + Pemetrexed Disodium + Ramucirumab AZD2936 + Carboplatin + Paclitaxel AZD2936 + Carboplatin + Nab-paclitaxel + Ramucirumab AZD2936 + Carboplatin + Nab-paclitaxel AZD2936 + Pemetrexed Disodium AZD2936 + Carboplatin + Pemetrexed Disodium + Ramucirumab AB248 + AZD2936 AZD2936 + Carboplatin + Paclitaxel + Ramucirumab
Age Groups:	adult \| senior
Covered Countries	USA \| TUR \| POL \| NLD \| ITA \| FRA \| ESP \| BRA \| BEL

Additional content available in CKB BOOST